Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 22442403)

1.

Pipeline, aneurysms and the FDA.

Hirsch JA, Chandra RV, Leslie-Mazwi TM.

J Neurointerv Surg. 2012 Jul;4(4):314; author reply 314. doi: 10.1136/neurintsurg-2012-010326. Epub 2012 Mar 22. No abstract available.

PMID:
22442403
2.

Treatment of intracranial aneurysms with the pipeline embolization device from a U.S. multicenter experience.

Stapleton CJ, Ogilvy CS.

World Neurosurg. 2013 Sep-Oct;80(3-4):231-3. doi: 10.1016/j.wneu.2013.07.008. Epub 2013 Jul 16. No abstract available.

PMID:
23871814
3.

Panacea or problem: flow diverters in the treatment of symptomatic large or giant fusiform vertebrobasilar aneurysms.

Siddiqui AH, Abla AA, Kan P, Dumont TM, Jahshan S, Britz GW, Hopkins LN, Levy EI.

J Neurosurg. 2012 Jun;116(6):1258-66. doi: 10.3171/2012.2.JNS111942. Epub 2012 Mar 9.

PMID:
22404673
4.

Have you been smoking something that is biologically active?

Cloft HJ.

AJNR Am J Neuroradiol. 2006 Feb;27(2):240-2. No abstract available.

5.

Safety, science, and sales: a request for valid clinical trials to assess new devices for endovascular treatment of intracranial aneurysms.

Raymond J, Guilbert F, Weill A, Roy D, LeBlanc P, GĂ©vry G, Chagnon M, Collet JP.

AJNR Am J Neuroradiol. 2004 Aug;25(7):1128-30. No abstract available.

7.

Comment: case series of pipeline embolization device (PED) application in vertebrobasilar aneurysms.

Serrone J, Ringer A.

Neurosurgery. 2013 Jun;72(6):889. No abstract available.

PMID:
23828951
8.

Clarification: 510k is premarket notification; it provides no patent or FDA approval.

Burkhart CG.

J Drugs Dermatol. 2008 Feb;7(2):105. No abstract available.

PMID:
18335644
9.

Cosmetic medical devices and their FDA regulation.

Newburger AE.

Arch Dermatol. 2006 Feb;142(2):225-8. No abstract available.

PMID:
16490851
10.

High hopes for new FDA law.

Kohl M.

J Refract Surg. 1998 Mar-Apr;14(2):98. No abstract available.

PMID:
9574738
11.

U.S. Senate limits FDA testing.

Kohl M.

J Refract Surg. 1997 Nov-Dec;13(7):612. No abstract available.

PMID:
9427196
12.

Foreword. Report 2012: Intracranial aneurysms: Clips or coils.

Bojanowski MW, McLaughlin N, Raymond J, Roy D.

Neurochirurgie. 2012 Apr-Jun;58(2-3):59-60. doi: 10.1016/j.neuchi.2012.03.005. English, French. No abstract available.

PMID:
22537590
13.

Ejecting the FDA from the courtroom.

[No authors listed]

Lancet. 2004 Aug 21-27;364(9435):638. No abstract available.

PMID:
15325808
14.

Curative cerebrovascular reconstruction with the Pipeline embolization device: the emergence of definitive endovascular therapy for intracranial aneurysms.

Fiorella D, Lylyk P, Szikora I, Kelly ME, Albuquerque FC, McDougall CG, Nelson PK.

J Neurointerv Surg. 2009 Jul;1(1):56-65. doi: 10.1136/jnis.2009.000083. Epub 2009 Jun 16.

PMID:
21994109
15.

Judicial review of FDA preemption determinations.

Frost A.

Food Drug Law J. 1999;54(3):367-88. No abstract available.

PMID:
11797704
16.

Cardiovascular and neurological devices; reclassification of two embolization devices. Final rule.

Food and Drug Administration, HHS.

Fed Regist. 2004 Dec 29;69(249):77898-900.

17.

FDA panel gives cautious signal to summit.

Moretti M.

J Refract Corneal Surg. 1994 Nov-Dec;10(6):613-4. No abstract available.

PMID:
7719529
18.

The FDA and the spine surgeon.

Ducker TB.

J Spinal Disord. 1999 Aug;12(4):277-9. No abstract available.

PMID:
10451041
19.

FDA begins to act against black box excimer lasers.

Kohl M.

J Refract Surg. 1997 Jul-Aug;13(4):336-8. No abstract available.

PMID:
9268930
20.

The FDA, preemption, and the Supreme Court.

Glantz LH, Annas GJ.

N Engl J Med. 2008 May 1;358(18):1883-5. doi: 10.1056/NEJMp0802108. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk